CPRX - Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction. The company is developing CPP-109, which is based on the chemical compound gamma-vinyl-GABA for the treatment of addiction to cocaine, methamphetamine, and other addictive substances. It also intends to develop CPP-109 to treat other addictions, such as addictions to nicotine, prescription pain medications, alcohol, and marijuana, as well as treatments for obsessive-compulsive disorders, including obesity and compulsive gambling. In addition, Catalyst Pharmaceutical Partners, through a worldwide license agreement with Brookhaven National Laboratory, owns interest primarily in nine patents relating to the right to use vigabatrin to treat various substance addictions.
 |
